Myriad's EndoPredict offers better prediction of breast cancer recurrence, analysis s
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.